GeoVax Labs, Inc. (NASDAQ:GOVX) Sees Significant Increase in Short Interest

Posted by Stacy Sanders on Jul 11th, 2024

GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 1,260,000 shares, a growth of 1,056.0% from the June 15th total of 109,000 shares. Based on an average daily volume of 2,820,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 50.6% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of GeoVax Labs in a research report on Tuesday, July 2nd.

Get Our Latest Research Report on GOVX

Institutional Trading of GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC purchased a new stake in shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned 91.38% of GeoVax Labs as of its most recent filing with the SEC. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Stock Down 8.4 %

Shares of NASDAQ GOVX traded down $0.27 during midday trading on Thursday, reaching $2.93. 1,001,443 shares of the stock traded hands, compared to its average volume of 1,413,533. GeoVax Labs has a one year low of $1.09 and a one year high of $10.24. The company’s 50 day moving average is $1.99 and its 200 day moving average is $2.61.

GeoVax Labs (NASDAQ:GOVX – Get Free Report) last posted its earnings results on Tuesday, May 14th. The company reported ($2.47) EPS for the quarter. As a group, equities analysts predict that GeoVax Labs will post -7.41 EPS for the current fiscal year.

About GeoVax Labs

(Get Free Report)

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.